AI-Designed Drug Rentosertib Shows 3-4 Years of Biological Age Reversal in Phase IIa Trial
Dr_Singularity · x · 2026-10-05
Insilico Medicine's AI-discovered and AI-designed drug rentosertib, originally developed for idiopathic pulmonary fibrosis, produced a striking secondary result in a Phase IIa trial: all 6 proteomic aging clocks measured the 42 patients as biologically younger after treatment.
- The strongest regimen showed 3-4 years of predicted biological age reversal after just four weeks, with one clock indicating up to 6 years
- The target TNIK was identified by AI, and the molecule itself was designed by generative AI
- The drug is advancing toward Phase III for lung fibrosis
CEO Alex Zhavoronkov cautioned the results are early-stage, but if confirmed it would be a landmark case for AI drug discovery and aging research.
Related event: AI-Designed Drug Shows 3-4 Years of Biological Age Reversal in Human Trial(3 posts)→
More from Research
- Matt Green muses: are n^25 galactic algorithms normal, or a glimpse of provable Algorithmica? — matthew_d_green · 2026-11-20
- MIT and NVIDIA's QDA uses agents to auto-design LLM quantization recipes, beating top public ones by up to 2.2 points — omarsar0 · 2026-11-20
- AI-powered forensic metascience: auditing 7 million papers, 500K files scanned, 100+ issues found — gleech · 2026-11-20
- Harmonic's Aristotle writes proven-correct fusion plasma controllers in C and Verilog in 4 hours — satnam6502 · 2026-11-20
- Interp4discovery workshop on interpretability for scientific discovery at NeurIPS, Dec 12 — begusgasper · 2026-11-20
- Talk compares tabular foundation models TabPFN, TabICR vs gradient boosting — saheedniyi_02 · 2026-11-20